Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020

Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0048621. doi: 10.1128/AAC.00486-21. Epub 2021 Jul 16.

Abstract

Aztreonam-avibactam is a drug combination pending phase 3 clinical trials and is suggested for treatment of severe infections caused by metallo-beta-lactamase (MBL)-producing Enterobacterales by combining ceftazidime-avibactam and aztreonam. Beginning in 2019, four Antibiotic Resistance Laboratory Network regional laboratories offered aztreonam-avibactam susceptibility testing by broth microdilution. For 64 clinical isolates tested, the MIC50 and MIC90 values of aztreonam-avibactam were 0.5/4 μg/ml and 8/4 μg/ml, respectively. Aztreonam-avibactam displayed potent in vitro activity against the MBL-producing Enterobacterales tested.

Keywords: Enterobacterales; MBL; antibiotic resistance; antimicrobial combinations; aztreonam-avibactam; beta-lactamases; carbapenemases; susceptibility testing.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Azabicyclo Compounds / pharmacology
  • Aztreonam* / pharmacology
  • Ceftazidime
  • Drug Combinations
  • Drug Resistance, Microbial
  • Humans
  • Laboratories
  • Microbial Sensitivity Tests
  • beta-Lactamases* / genetics

Substances

  • Anti-Bacterial Agents
  • Azabicyclo Compounds
  • Drug Combinations
  • avibactam
  • Ceftazidime
  • beta-Lactamases
  • Aztreonam